SAN CARLOS, Calif., July 14, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has received the Force for Change Illuminator award from LWE, accepted by Sheetal Parmar, Natera’s VP of Medical Affairs.
The Force for Change awards are held in partnership with LWE, an organization that has recognized over 500 outstanding women leaders and innovative companies over the past decade. In this unprecedented year, LWE focused on organizations that have made a significant and positive impact on the lives of others during the COVID-19 pandemic.
"We are delighted to honor Natera with the Force for Change Illuminator award. This year, we carefully selected individuals and companies that we believe are paving the way for a brighter future and are leaders in their respective fields," said Linda Wellbrock, founder and CEO of LWE. "We are inspired by Natera’s mission to change the way disease is managed worldwide. The company’s programs to support patients, healthcare providers, and employees during the pandemic made it clear to us that Natera is a true force for change and driver of innovation."
Sheetal Parmar, who leads the Clinical Services and Medical Education teams at Natera, and is co-chair of Women of Natera, an employee resource group that supports workplace equality and diversity, was recognized for her individual contributions to Natera’s mission and values. "We are proud to not only be recognized for our scientific advances and COVID-19 efforts, but also for our commitment to promoting diversity at all levels of our business," said Parmar. "Embracing diverse backgrounds and viewpoints has been a catalyst for innovation and growth, enabling us to develop best-in-class products and services that uniquely meet the needs of our patients and healthcare providers."
The Force for Change awards ceremony will be held virtually on November 2, 2020. Visit lweworld.com to learn more.
Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on reproductive health, oncology, and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Paul Greenland, VP of Corporate Marketing, email@example.com
SOURCE Natera, Inc.